Table 1 Characteristics of the eligible studies included in the meta-analysis
Study | Country | Year | Sample size | Mean age(Yr) | Percentage of men (%) | Study population | Outcome | Genotyping method | Quality score | |||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Case | Control | Case | Control | Case | Control | |||||||
Lacquemant[16] | Switzerland | 2003 | 107 | 181 | / | / | / | / | T2D | CAD | Other | 9 |
Lacquemant[16] | France | 2003 | 55 | 134 | / | / | / | / | T2D | CAD | Other | 9 |
Bacci[17] | Italy | 2004 | 142 | 234 | 64.0 | 60.0 | 64.1 | 43.2 | T2D | CHD | Other | 8 |
Ohashi [30] | Japan | 2004 | 383 | 368 | 63.0 | 62.3 | 70.5 | 65.2 | General | CAD | TaqMan | 7 |
Stenvinkel [31] | America | 2004 | 63 | 141 | / | / | / | / | Renal disease | CVD | Other | 7 |
Filippi [32] | Italy | 2005 | 580 | 466 | 60.3 | 50.9 | 76.9 | 49.6 | General | CAD | Other | 9 |
Ru [33] | China | 2005 | 131 | 136 | 51.3 | 50.6 | 56.2 | 52.9 | General | CHD | TaqMan | 6 |
Qi [21] | America | 2005 | 239 | 640 | 59.6 | 55.0 | 100 | 100 | T2D | CVD | TaqMan | 10 |
Qi [34] | America | 2006 | 285 | 704 | 47.0 | 44.0 | 0 | 0 | T2D | CVD | TaqMan | 10 |
Gable [35] | UK | 2006 | 266 | 2727 | 56.0 | 56.6 | 100 | 100 | General | CVD | PCR-RFLP | 12 |
Gable [35] | UK | 2006 | 530 | 564 | 56.0 | 56.6 | 100 | 100 | General | MI | PCR-RFLP | 12 |
Wang [36] | China | 2006 | 120 | 131 | / | / | / | / | General | CHD | PCR-RFLP | 7 |
Hegener[37] | America | 2006 | 341 | 341 | 60.2 | 60.1 | 100 | 100 | General | MI | TaqMan | 11 |
Hegener[37] | America | 2006 | 259 | 259 | 62.1 | 61.7 | 100 | 100 | General | Stroke | TaqMan | 11 |
Jung[38] | Korea | 2006 | 88 | 86 | 60.4 | 53.4 | 71.6 | 50 | General | CAD | TaqMan | 8 |
Pischon[39] | America | 2007 | 1036 | 2071 | 62.9 | 62.8 | 51.7 | 51.7 | General | CHD | TaqMan | 11 |
Lu[40] | China | 2007 | 131 | 135 | 58.4 | 60.7 | 68.9 | 62.6 | General | CHD | PCR-RFLP | 7 |
Liang[41] | China | 2008 | 100 | 100 | 45.7 | 60.8 | 66.0 | 65.0 | General | CHD | PCR-RFLP | 6 |
Yamada[42] | Japan | 2008 | 313 | 971 | 67.0 | 68.2 | 61.7 | 48.7 | MetS | ACI | Other | 9 |
Oguri[19] | Japan | 2009 | 773 | 1114 | 64.8 | 68.3 | 77.2 | 50.8 | MetS | MI | Other | 10 |
Chang[43] | China | 2009 | 600 | 718 | 63.8 | 51.1 | 78.3 | 53.4 | General | CAD | PCR-RFLP | 9 |
Foucan[44] | France | 2009 | 57 | 159 | 68.0 | 63.0 | 51.0 | 36.0 | T2D | CAD | TaqMan | 7 |
Zhang[45] | China | 2009 | 205 | 130 | 65.0 | 63.0 | 63.4 | 50.4 | General | CHD | PCR-RFLP | 8 |
Zhong[46] | China | 2010 | 198 | 237 | 60.6 | 54.5 | 54.0 | 46.0 | General | CAD | TaqMan | 10 |
De Caterina[47] | Italy | 2010 | 1864 | 1864 | 39.5 | 39.6 | 88.8 | 88.8 | General | MI | Other | 13 |
Xu[48] | China | 2010 | 153 | 73 | 66.3 | 66.3 | 53.6 | 53.4 | General | CHD | PCR-RFLP | 8 |
Al-Daghri[49] | Saudi Arabia | 2010 | 123 | 295 | 69.4 | 60.7 | 60 | 70 | T2D | CAD | PCR-RFLP | 8 |
Prior[20] | UK | 2010 | 85 | 298 | 71.0 | 68.2 | 63.6 | 50.6 | General | CHD | PCR-RFLP | 7 |
Chiodini[18] | Italy | 2010 | 503 | 503 | 56.5 | 54.7 | 89.3 | 95.8 | General | MI | TaqMan | 10 |
Rodriguez[50] | Spain | 2010 | 119 | 555 | / | / | / | / | RA | CVD | TaqMan | 9 |
Leu[51] | China | 2010 | 80 | 3330 | 59.1 | 50.0 | 52.5 | 45.3 | General | stroke | Other | 10 |
Liu[52] | China | 2010 | 302 | 338 | 65.7 | 64.4 | 63.9 | 62.1 | General | stroke | PCR-RFLP | 9 |
Chen[53] | China | 2010 | 357 | 345 | 63.6 | 53.7 | 60.2 | 60.9 | General | stroke | TaqMan | 8 |
Sabouri[54] | UK | 2011 | 329 | 106 | 58.4 | 47.6 | 64.1 | 56.3 | General | CAD | PCR-RFLP | 8 |
Esteghamati[55] | Iran | 2011 | 144 | 127 | 61.1 | 51.1 | 38.6 | 55.9 | General | CAD | PCR-RFLP | 10 |
Boumaiza[56] | Tunisia | 2011 | 212 | 104 | 60.6 | 59.4 | 69.3 | 55.8 | General | CAD | PCR-RFLP | 10 |
Katakami[57] | Japan | 2012 | 213 | 2424 | 58.1 | 54.6 | 66.2 | 60.7 | T2D | CVD | Other | 11 |